A detailed history of Ashton Thomas Securities, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ashton Thomas Securities, LLC holds 69 shares of HALO stock, worth $3,280. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69
Holding current value
$3,280
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$51.3 - $64.42 $3,539 - $4,444
69 New
69 $3.95 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Ashton Thomas Securities, LLC Portfolio

Follow Ashton Thomas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ashton Thomas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ashton Thomas Securities, LLC with notifications on news.